Pharmacokinetic evaluation of armodafinil for the treatment of bipolar depression

Bibliography

• Diagnostic and statistical manual of mental health disorders. 4th edition. American Psychiatric Association; Washington DC: 1994
   Google Scholar
• Merikangas KR, Jin R, He JP, Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. Arch Gen Psychiatry 2011;68(3):241-51
   PubMed Web of Science ®Google Scholar
• Treuer T, Tohen M. Predicting the course and outcome of bipolar disorder: a review. Eur Psychiatry 2010;25(6):328-33
   PubMed Web of Science ®Google Scholar
• Novick DM, Swartz HA, Frank E. Suicide attempts in bipolar I and bipolar II disorder: a review and meta-analysis of the evidence. Bipolar Disord 2010;12(1):1-9
   PubMed Web of Science ®Google Scholar
• Perlis RH, Ostacher MJ, Patel JK, Predictors of recurrence in bipolar disorder: primary outcomes from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am J Psychiatry 2006;163(2):217-24
   PubMed Web of Science ®Google Scholar
• Fagiolini A, Kupfer DJ, Masalehdan A, Functional impairment in the remission phase of bipolar disorder. Bipolar Disord 2005;7(3):281-5
   PubMed Web of Science ®Google Scholar
• Michalak EE, Yatham LN, Lam RW. Quality of life in bipolar disorder: a review of the literature. Health Qual Life Outcomes 2005;3:72
   PubMedGoogle Scholar
• Yatham LN, Kennedy SH, Schaffer A, Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disord 2009;11(3):225-55
   PubMed Web of Science ®Google Scholar
• Grunze H, Vieta E, Goodwin GM, The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2009 on the treatment of acute mania. World J Biol Psychiatry 2009;10(2):85-116
   PubMed Web of Science ®Google Scholar
• Yildiz A, Vieta E, Leucht S, Baldessarini RJ. Efficacy of antimanic treatments: meta-analysis of randomized, controlled trials. Neuropsychopharmacology 2011;36(2):375-89
   PubMed Web of Science ®Google Scholar
• Calabrese JR, Hirschfeld RM, Frye MA, Reed ML. Impact of depressive symptoms compared with manic symptoms in bipolar disorder: results of a U.S. community-based sample. J Clin Psychiatry 2004;65(11):1499-504
   PubMed Web of Science ®Google Scholar
• Vieta E, Locklear J, Gunther O, Treatment options for bipolar depression: a systematic review of randomized, controlled trials. J Clin Psychopharmacol 2010;30(5):579-90
   PubMed Web of Science ®Google Scholar
• Cruz N, Sanchez-Moreno J, Torres F, Efficacy of modern antipsychotics in placebo-controlled trials in bipolar depression: a meta-analysis. Int J Neuropsychopharmacol 2010;13(1):5-14
   PubMed Web of Science ®Google Scholar
• Tohen M, Vieta E, Calabrese J, Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 2003;60(11):1079-88
   PubMed Web of Science ®Google Scholar
• De Fruyt J, Deschepper E, Audenaert K, Second generation antipsychotics in the treatment of bipolar depression: a systematic review and meta-analysis. J Psychopharmacol 2012;26(5):603-17
   PubMed Web of Science ®Google Scholar
• Grunze H, Vieta E, Goodwin GM, The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2010 on the treatment of acute bipolar depression. World J Biol Psychiatry 2010;11(2):81-109
   PubMed Web of Science ®Google Scholar
• Geddes JR, Calabrese JR, Goodwin GM. Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials. Br J Psychiatry 2009;194(1):4-9
   PubMed Web of Science ®Google Scholar
• Bond DJ, Lam RW, Yatham LN. Divalproex sodium versus placebo in the treatment of acute bipolar depression: a systematic review and meta-analysis. J Affect Disord 2010;124(3):228-34
   PubMed Web of Science ®Google Scholar
• Frye MA, Grunze H, Suppes T, A placebo-controlled evaluation of adjunctive modafinil in the treatment of bipolar depression. Am J Psychiatry 2007;164(8):1242-9
   PubMed Web of Science ®Google Scholar
• Tondo L, Vazquez G, Baldessarini RJ. Mania associated with antidepressant treatment: comprehensive meta-analytic review. Acta Psychiatr Scand 2010;121(6):404-14
   PubMed Web of Science ®Google Scholar
• Ghaemi SN, Wingo AP, Filkowski MA, Baldessarini RJ. Long-term antidepressant treatment in bipolar disorder: meta-analyses of benefits and risks. Acta Psychiatr Scand 2008;118(5):347-56
   PubMed Web of Science ®Google Scholar
• Sidor MM, Macqueen GM. Antidepressants for the acute treatment of bipolar depression: a systematic review and meta-analysis. J Clin Psychiatry 2011;72(2):156-67
   PubMed Web of Science ®Google Scholar
• Malhi GS, Tanious M, Das P, Berk M. The science and practice of lithium therapy. Aust NZ J Psychiatry 2012;46(3):192-211
   PubMed Web of Science ®Google Scholar
• Pramyothin P, Khaodhiar L. Metabolic syndrome with the atypical antipsychotics. Curr Opin Endocrinol Diabetes Obes 2010;17(5):460-6
   PubMed Web of Science ®Google Scholar
• Gao K, Kemp DE, Ganocy SJ, Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review. J Clin Psychopharmacol 2008;28(2):203-9
   PubMed Web of Science ®Google Scholar
• NUVIGIL™ (armodafinil) tablets (C-IV). Cephalon, Inc. Frazer, PA: Cephalon, Inc. 2010. Available from: http://www.nuvigil.com/media/Full_Prescribing_Information.pdf [Last accessed 21 March 2012]
   Google Scholar
• Calabrese JR, Ketter TA, Youakim JM, Adjunctive armodafinil for major depressive episodes associated with bipolar I disorder: a randomized, multicenter, double-blind, placebo-controlled, proof-of-concept study. J Clin Psychiatry 2010;71(10):1363-70
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. U.S. National Institutes of Health. Bethesda, MD: US National Library of Medicine. 2000. Available from: http://www.clinicaltrials.gov [Last accessed 21 March 2012]
   Google Scholar
• Dinges DF, Arora S, Darwish M, Niebler GE. Pharmacodynamic effects on alertness of single doses of armodafinil in healthy subjects during a nocturnal period of acute sleep loss. Curr Med Res Opin 2006;22(1):159-67
   PubMed Web of Science ®Google Scholar
• Wisor JP, Dement WC, Aimone L, Armodafinil, the R-enantiomer of modafinil: wake-promoting effects and pharmacokinetic profile in the rat. Pharmacol Biochem Behav 2006;85(3):492-9
   PubMed Web of Science ®Google Scholar
• Beck P, Odle A, Wallace-Huitt T, Modafinil increases arousal determined by P13 potential amplitude: an effect blocked by gap junction antagonists. Sleep 2008;31(12):1647-54
   PubMed Web of Science ®Google Scholar
• Urbano FJ, Leznik E, Llinas RR. Modafinil enhances thalamocortical activity by increasing neuronal electrotonic coupling. Proc Natl Acad Sci USA 2007;104(30):12554-9
   PubMed Web of Science ®Google Scholar
• Code of Federal Regulations Title 21, Section 1308.14 Schedule IV. U.S. Departement of Justice, Drug Enforcement Administration. Springfield, VA: Office of Diversion Control. 2011. Available from: http://www.deadiversion.usdoj.gov/21cfr/cfr/1308/1308_14.htm [Last accessed 21 March 2012]
   Google Scholar
• List of Prohibited Substances and Methods. World Anti-Doping Agency. Montreal: World Anti-Doping Agency. 2011. Available from: http://list.wada-ama.org [Last accessed 21 March 2012]
   Google Scholar
• Darwish M, Kirby M, Hellriegel ET, Pharmacokinetic profile of armodafinil in healthy subjects: pooled analysis of data from three randomized studies. Clin Drug Investig 2009;29(2):87-100
   PubMed Web of Science ®Google Scholar
• Darwish M, Kirby M, Hellriegel ET, Robertson P Jr. Armodafinil and modafinil have substantially different pharmacokinetic profiles despite having the same terminal half-lives: analysis of data from three randomized, single-dose, pharmacokinetic studies. Clin Drug Investig 2009;29(9):613-23
   PubMed Web of Science ®Google Scholar
• Darwish M, Kirby M, Hellriegel ET. Comparison of steady-state plasma concentrations of armodafinil and modafinil late in the day following morning administration: post hoc analysis of two randomized, double-blind, placebo-controlled, multiple-dose studies in healthy male subjects. Clin Drug Investig 2009;29(9):601-12
   PubMed Web of Science ®Google Scholar
• Robertson P Jr, Hellriegel ET. Clinical pharmacokinetic profile of modafinil. Clin Pharmacokinet 2003;42(2):123-37
   PubMed Web of Science ®Google Scholar
• Wong YN, King SP, Simcoe D, Open-label, single-dose pharmacokinetic study of modafinil tablets: influence of age and gender in normal subjects. J Clin Pharmacol 1999;39(3):281-8
   PubMed Web of Science ®Google Scholar
• Darwish M, Kirby M, Robertson P Jr, Hellriegel ET. Interaction profile of armodafinil with medications metabolized by cytochrome P450 enzymes 1A2, 3A4 and 2C19 in healthy subjects. Clin Pharmacokinet 2008;47(1):61-74
   PubMed Web of Science ®Google Scholar
• Darwish M, Kirby M, Hellriegel ET, Systemic exposure to armodafinil and its tolerability in healthy elderly versus young men: an open-label, multiple-dose, parallel-group study. Drugs & Aging 2011;28(2):139-50
   PubMed Web of Science ®Google Scholar
• Menza MA, Kaufman KR, Castellanos A. Modafinil augmentation of antidepressant treatment in depression. J Clin Psychiatry 2000;61(5):378-81
   PubMed Web of Science ®Google Scholar
• Camacho A, Ng B, Frye MA. Modafinil for bipolar depression with comorbid methamphetamine abuse. Am J Addict 2010;19(2):190-1
   PubMed Web of Science ®Google Scholar
• Even C, Thuile J, Santos J, Bourgin P. Modafinil as an adjunctive treatment to sleep deprivation in depression. J Psychiatry Neurosci 2005;30(6):432-3
   PubMed Web of Science ®Google Scholar
• Fernandes PP, Petty F. Modafinil for remitted bipolar depression with hypersomnia. Ann Pharmacother 2003;37(12):1807-9
   PubMed Web of Science ®Google Scholar
• Berigan T. Modafinil treatment of excessive sedation associated with divalproex sodium. Can J Psychiatry 2004;49(1):72-3
   PubMed Web of Science ®Google Scholar
• Schoenknecht P, Olbrich S, Sander C, Treatment of acute mania with modafinil monotherapy. Biol Psychiatry 2010;67(11):e55-7
   PubMedGoogle Scholar
• Harsh JR, Hayduk R, Rosenberg R, The efficacy and safety of armodafinil as treatment for adults with excessive sleepiness associated with narcolepsy. Curr Med Res Opin 2006;22(4):761-74
   PubMed Web of Science ®Google Scholar
• Roth T, White D, Schmidt-Nowara W, Effects of armodafinil in the treatment of residual excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome: a 12-week, multicenter, double-blind, randomized, placebo-controlled study in nCPAP-adherent adults. Clin Ther 2006;28(5):689-706
   PubMed Web of Science ®Google Scholar
• Biederman J, Swanson JM, Wigal SB, Efficacy and safety of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, flexible-dose study. Pediatrics 2005;116(6):e777-84
   PubMed Web of Science ®Google Scholar
• Wingo AP, Ghaemi SN. Frequency of stimulant treatment and of stimulant-associated mania/hypomania in bipolar disorder patients. Psychopharmacol Bull 2008;41(4):37-47
   PubMed Web of Science ®Google Scholar
• Crosby MI, Bradshaw DA, McLay RN. Severe mania complicating treatment of narcolepsy with cataplexy. J Clin Sleep Med 2011;7(2):214-16
   PubMed Web of Science ®Google Scholar
• Nasr S, Wendt B, Steiner K. Absence of mood switch with and tolerance to modafinil: a replication study from a large private practice. J Affect Disord 2006;95(1-3):111-14
   PubMed Web of Science ®Google Scholar
• Darwish M, Bond M, Hellriegel ET, Investigation of a possible interaction between quetiapine and armodafinil in patients with schizophrenia: an open-label, multiple-dose study. J Clin Pharmacol 2011; published online 8 september 2011. doi: 10.1177/0091270011414572
   Web of Science ®Google Scholar
• Drugs@FDA: FDA Approved Drug Products; U.S. Food and Drug Administration. Silver Spring, MD: U.S. Food and Drug Administration, 2012. Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm [Last accessed 23 March 2012]
   Google Scholar
• Kaplan KA, Gruber J, Eidelman P, Hypersomnia in inter-episode bipolar disorder: does it have prognostic significance? J Affect Disord 2011;132(3):438-44
   PubMed Web of Science ®Google Scholar
• Candy M, Jones L, Williams R, Psychostimulants for depression. Cochrane Database Syst Rev 2008(2):CD006722
   Google Scholar
• Saavedra-Velez C, Yusim A, Anbarasan D, Lindenmayer JP. Modafinil as an adjunctive treatment of sedation, negative symptoms, and cognition in schizophrenia: a critical review. J Clin Psychiatry 2009;70(1):104-12
   PubMed Web of Science ®Google Scholar
• Brady KT, Gray KM, Tolliver BK. Cognitive enhancers in the treatment of substance use disorders: clinical evidence. Pharmacol Biochem Behav 2011;99(2):285-94
   PubMed Web of Science ®Google Scholar
• Joos L, Docx L, Schmaal L, Modafinil in psychiatric disorders: the promising state reconsidered. Tijdschr Psychiatr 2010;52(11):763-73
   PubMedGoogle Scholar